Chronic hepatitis C is an important cause of liver disease. Although treatment with pegylated interferon and ribavirin is covered by national health insurance in Taiwan, its contraindications, side effects and limited results make this treatment still unsatisfactory. In recent years, researches of interferon-free treatment with all-oral direct-acting antiviral agents (DAA) for chronic hepatitis C progressed rapidly, revealed good treatment effects and these agents are approved in Europe, United states and Japan. These treatments are expensive, have not been covered by national health insurance, and have not been approved in Taiwan yet. However, after filing special applications, physicians still could consider all-oral DAA to treat patients who indeed require and could afford these new agents in Taiwan.